In this Dec.18, 2014, photograph, scientist Christopher Kistler checks on experiments in bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. On June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study.
In this Dec.18, 2014, photograph, scientist Christopher Kistler checks on experiments in bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. On June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study. Mel Evans AP
In this Dec.18, 2014, photograph, scientist Christopher Kistler checks on experiments in bio-reactors in a laboratory at the Merck company facilities in Kenilworth, N.J. On June 27, 2017, Merck & Co. said a new type of cholesterol drug, in testing for many years, reduced heart attacks, deaths and other complications of heart disease in a huge late-stage study. Mel Evans AP

Andres Oppenheimer

June 30, 2017 7:00 AM

Latin America has a surplus of talent — and a shortage of innovation

  Comments  

Videos

About Andres Oppenheimer

Andres Oppenheimer

@oppenheimera

Andres Oppenheimer is a syndicated columnist, and anchor of the TV Show "Oppenheimer Presenta." He is a member of the Miami Herald team that won the 1987 Pulitzer Prize.